Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study

被引：0
|
作者：
Rathkopf, Dana E.
Roubaud, Guilhem
Chi, Kim N.
Efstathiou, Eleni
Attard, Gerhardt
Olmos, David
Small, Eric J.
Saad, Marniza
Castro, Elena
Kim, Won
Wu, Daphne
Bertzos, Kristi
Dibaj, Shiva
Zhang, Jenny
Francis, Peter St. John
Smith, Matthew Raymond
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Inst Bergonie, Dept Med Oncol, Bordeaux, France
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Houston Methodist Hosp, Dept Med Oncol, Houston, TX USA
[5] UCL, London, England
[6] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre, Madrid, Spain
[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[8] Univ Malaya, Fac Med, Dept Clin Oncol, Kuala Lumpur, Malaysia
[9] Univ Hosp Virgen de la Victoria HUVV, Malaga, Spain
[10] Janssen R&D US, Los Angeles, CA USA
[11] Janssen Res & Dev LLC, Los Angeles, CA USA
[12] Janssen Global Commercial Strategy Org, Horsham, PA USA
[13] Janssen Res & Dev LLC, San Diego, CA USA
[14] Johnson&Johnson, Spring House, PA USA
[15] Janssen Res & Dev LLC, Raritan, NJ USA
[16] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[17] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：105 / 105
页数：1
相关论文
共 50 条
  • [41] A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Attard, Gerhardt
    Merseburger, Axel S.
    Sternberg, Cora N.
    Cerbone, Linda
    Recine, Federica
    Jones, Robert J.
    Feyerabend, Susan
    Berruti, Alfredo
    Joniau, Steven
    Schatteman, Peter
    Geczi, Lajos
    Tenke, Peter
    Werbrouck, Patrick
    Lefresne, Florence
    Shelby, Florence Nave
    Lahaye, Marjolein
    Pick, Corinna
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [42] Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial
    Basch, Ethan
    Autio, Karen
    Ryan, Charles J.
    Mulders, Peter
    Shore, Neal
    Kheoh, Thian
    Fizazi, Karim
    Logothetis, Christopher J.
    Rathkopf, Dana
    Smith, Matthew R.
    Mainwaring, Paul N.
    Hao, Yanni
    Griffin, Thomas
    Li, Susan
    Meyers, Michael L.
    Molina, Arturo
    Cleeland, Charles
    LANCET ONCOLOGY, 2013, 14 (12): : 1193 - 1199
  • [43] PHASE 3 MAGNITUDE STUDY: RESULTS FROM SECOND INTERIM ANALYSIS OF NIRAPARIB WITH ABIRATERONE ACETATE AND PREDNISONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH AND WITHOUT HRR GENE ALTERATIONS
    Rathkopf, Dana E.
    Small, Eric
    Guckert, Mary
    Chi, Kim N.
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [44] Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
    Mehra, Niven
    Antonarakis, Emmanuel S.
    Park, Se Hoon
    Goh, Jeffrey C.
    McDermott, Raymond S.
    Gonzalez, Nuria Sala
    Fong, Peter C. C.
    Greil, Richard
    De Santis, Maria
    Yanez, Patricio Eduardo
    Huang, Yi-Hsiu
    Begbie, Stephen
    Rey, Felipe
    Kramer, Gero
    Suzuki, Hiroyoshi
    Saretsky, Todd L.
    Ghate, Sameer R.
    Cui, Yi
    Kim, Jeri
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [45] Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) - a Drug-Drug Interaction (DDI) Study With Dextromethorphan HBr and Theophylline
    Chi, K. N.
    Tolcher, A.
    Lee, P.
    Rosen, P.
    Molina, A.
    Jiao, J.
    Bernard, A.
    Tran, N.
    Acharya, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S502 - S503
  • [46] Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).
    George, Daniel J.
    Heath, Elisabeth I.
    Sartor, A. Oliver
    Sonpavde, Guru
    Berry, William R.
    Healy, Patrick
    Winters, Carolyn
    Riggan, Colleen
    Anand, Monika
    Kephart, Julie
    Milowsky, Matthew I.
    Fleming, Mark T.
    Balaji, K. C.
    Zhang, Tian
    Bitting, Rhonda L.
    Harrison, Michael Roger
    McNamara, Megan Ann
    Freedman, Jennifer A.
    Halabi, Susan
    Armstrong, Andrew J.
    Bruner, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
  • [47] Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).
    George, Daniel J.
    Halabi, Susan
    Fleming, Mark T.
    Heath, Elisabeth I.
    Tutrone, Ronald
    Sutton, Linda
    Whang, Young E.
    Lewis, Brian E.
    Humeniuk, Michael Sandon
    Harrison, Michael Roger
    Kephart, Julie
    Hurrelbrink, Julia
    Rasmussen, Julia
    Shobe, Kellie
    Anand, Monika
    Reyes-Martinez, Marco
    Howard, Lauren
    Patierno, Steven R.
    Freedman, Jennifer A.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
    Hahn, Andrew W.
    Patel, Darshan
    Gill, David Michael
    Froerer, Camryn
    Nussensveig, Roberto
    Poole, Austin
    Hale, Peter
    Farnham, James M.
    Maughan, Benjamin Louis
    Cannon-Albright, Lisa A.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [49] ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-naive metastatic castration-resistant prostate cancer (mCRPC)
    Attard, Gerhardt
    De Bono, Johann Sebastian
    Li, Weimin
    Molina, Arturo
    Griffin, Thomas W.
    Kheoh, Thian San
    Ricci, Deborah Sokol
    Zelinsky, Kathy
    Rathkopf, Dana E.
    Scher, Howard I.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] QT/QTc Studies of Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Analysis of 3 Phase 1/2 Studies
    Ryan, C. J.
    Danila, D. C.
    Tolcher, A.
    Chi, K. N.
    Tran, N.
    Knoblauch, R.
    Kheoh, T.
    Haqq, C. M.
    Scher, H. I.
    Molina, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S502 - S502
12345